Overweight breast cancer survivors treated with tamoxifen may have higher risk for arm lymphedema
the ONA take:
Breast cancer survivors with a body mass index (BMI) >25 who report the use of tamoxifen therapy may be at increased risk for arm lymphedema, according to a recent study published in the Journal of Cancer Survivorship.
For the study, researchers analyzed data from 43 women breast cancer who reported physician-diagnosed lymphedema during follow-up of the long-term quality of life (LTQOL) study in order to investigate whether an association exists between treatment-related risk factors and development of arm lymphedema.
Results showed that tamoxifen had a non-significant, positive association with arm lymphedema, but type of surgery, radiation, or chemotherapy had no impact on the risk of lymphedema development. Researchers found that the risk for developing arm lymphedema was particularly higher among overweight and obese women with a BMI greater than 25 who were treated with tamoxifen.
"Lymphedema risk may be another indication to consider a weight reduction program in breast cancer survivors," the authors conclude.
Breast cancer survivors with a body mass index (BMI) >25 who report the use of tamoxifen therapy may be at increased risk for arm lymphedema.
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Colorectal Cancer Rates Increased Sharply Among Generation X and Millennials
- Pneumonia Associated With Common Cold May Cause Fatal Illness in Stem Cell Transplant Recipients
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Screening Increases Early Palliative Care, Reduces Aggressive EOL Measures
- Antiperspirants/Deodorants and Breast Cancer (Fact Sheet)
- Risk of Second Cancers Increased in Hodgkin Lymphoma Survivors
- ONS Partners with ASCO CancerLinQ to Launch CancerLinQ® Ambassadors Program
- Characteristics of Clinical Trials and Barriers to Patient Enrollment Identified
- Exercise Improves Coping While Undergoing Chemotherapy for Advanced GI Cancer
- Genetic Similarity to BRCA1/BRCA2 Mutations May Impact Treatment Options
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|